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19 Abstract: The 18067 C>T polymorphism of XRCC3 gene has been considered to be implicated in the development of cervical and ovarian cancers,
20 but the results are inconsistent. Thus, we conducted a meta-analysis to assess the association of XRCC3 18067 C>T polymorphism with risk of
21 cervical and ovarian cancers. All studies on the association of XRCC3 18067 C>T polymorphism with cervical and ovarian cancers risk were retrieved.
22 Finally, a total of 17 studies including 10 studies with 5,637 cases and 10,057 controls on ovarian cancer and 7 studies with 1,112 cases and 1,233
23 controls on cervical cancer were selected. Overall, pooled results showed that the XRCC3 18067 C>T polymorphism was significantly associated with
24 increased risk of ovarian cancer (TC vs. CC: OR= 0.904, 95% CI= 0.841–0.972, p= 0.006; TT+TC vs. CC: OR= 0.914, 95% CI= 0.853–0.979,
25 p= 0.010) and cervical cancer (TC vs. CC: OR= 1.00, 95% CI= 1.066–1.585, p= 0.009). Further subgroup analysis by ethnicity revealed an
26 increased risk of cervical and ovarian cancer in Asians and Caucasians, respectively. The present meta-analysis inconsistent with the previous meta-
27 analysis suggests that the XRCC3 18067 C>T polymorphism might be implicated in the pathogenesis of cervical and ovarian cancers.
28 Keywords: cervical cancer, ovarian cancer, XRCC3 gene, polymorphism, meta-analysis
29 Introduction
30 Cervical and ovarian cancers remain two of the leading
31 cause of cancer mortality worldwide among women
32 and the most common site in several low-income
33 countries [1, 2]. It is widely accepted that certain
34 oncogenic types of human papilloma virus (HPV) are
35 essential cause of cervical cancer development [3]. Almost
36 100% of women with a diagnosis of cervical cancer
37have been found to have had an HPV infection [4].
38Ovarian cancer is characterized by few early symptoms,
39presentation at an advanced stage, and poor survival [5, 6].
40The exact causes of ovarian cancer are not known1 Q2.
41Relatively few risk factors for ovarian cancer have been
42identified, including age, parity, oral contraceptive use,
43lifestyle factors, and family history of breast or ovarian
44cancer, many of these are not easily modifiable on the
45population level [4, 7].
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46 Genome-wide association studies have been extremely
47 successful at finding susceptibility loci for cervical and
48 ovarian cancers [8]. Molecular epidemiological studies
49 have been conducted with the candidate gene approach
50 to identify susceptibility genes for cervical and ovarian
51 cancers, many of which have showed inconsistent
52 result [9]. DNA repair plays an important role in the
53 maintenance of genomic integrity by correcting DNA
54 alterations caused by endogenous and exogenous
55 genotoxic agents [10]. At present, several DNA repair
56 genes (e.g., XPD, XPF, ERCC1, XRCC1, XRCC3,
57 XPA, XPB, XPC, and hOGG1) have been reported to
58 be associated with cervical and ovarian cancers, and the
59 X-ray cross-complementing group 3 (XRCC3) gene has
60 received an increasing attention [11, 12].
61 The humanXRCC3 gene (MIM: 600675) is localized
62 on chromosomes 14q32.3 [13]. It is involved in the
63 homologous recombination repair (HR) pathway,
64 responsible for DNA double-strand breaks [14]. XRCC3
65 is a polymorphic gene where many SNPs have been
66 already described. Several polymorphisms in the XRCC3
67 gene have been described to affect the enzyme function
68 and/or its interaction with other proteins involved in
69 DNA damage and repair [13, 14]. Of these, C18607T
70 transition (rs861539) at exon 7 resulting in an amino
71 acid change at codon 241 (Thr241Met) has been
72 studied frequently [13]. This polymorphism has been
73 reported to be associated with the development of some
74 cancers, such as bladder, skin, breast, lung, and colorectal
75 cancers [15].
76 Several epidemiological studies were conducted in
77 recent years to evaluate the association of the XRCC3
78 18067 C>T polymorphism with cervical and ovarian
79 cancers [16, 17]. Some studies have shown a significant
80 statistical correlation of this polymorphism with cervical
81 and ovarian cancers, whereas others did not find any such
82 association. Thus, these inconsistent results fail to clarify
83 this complicated genetic relationship, presumably due to
84 small sample size in each published study, various genetic
85 backgrounds, and possible selection bias. To reliably
86 demonstrate the effect of XRCC3 18067 C>T polymor-
87 phism on cervical and ovarian cancer risks, we performed
88 a comprehensive systematic review and meta-analysis of
89 all eligible studies to resolve this pivotal issue.
90 Materials and Methods
91 Study identification and selection
92 This meta-analysis conformed to the Preferred Reporting
93 Items for Systematic Reviews and Meta-analyses criteria.
94 Two investigators independently searched the MED-
95 LINE (PubMed), Google Scholar, Web of Science
96 (Thomson-Reuters), Scientific Information Database
97 (SID), Chinese National Knowledge Infrastructure
98(CNKI), the Chinese Wanfang, and the Chinese VIP
99databases for eligible articles examined the association of
100XRCC3 18067 C>T polymorphism with cervical and
101ovarian cancer risks published up to January 30, 2019.
102The following terms were utilized: (“ovarian cancer” OR
103“cervical cancer”) AND (“X-ray repair cross comple-
104menting 3” OR “XRCC3”) AND (“XRCC3 18067
105C>T” OR “Thr241Met” OR “rs861539”) AND
106(“polymorphism”, OR “mutation” OR “variant” OR
107“gene” OR “genotype” OR “SNP” OR “allele”). The
108search was performed without any restrictions on
109language and was focused on studies that had been
110conducted in humans. In addition, manual searching of
111the references of eligible studies, reviews and related
112meta-analyses, and the abstracts presented at relevant
113conferences were performed to identify potentially
114relevant studies. If there were multiple reports of the
115same study or overlapping data, only the study with the
116largest sample sizes or the most recent one should be in
117the final analysis.
118Data extraction
119Information was carefully extracted from all eligible stud-
120ies independently by two investigators according to the
121inclusion criteria listed above, and potential disagree-
122ments were resolved by consensus. The following data
123were collected from each study: name of first author,
124publication year, country where the study was conducted,
125racial descent (categorized as Asian, Caucasian, or mixed
126descent), polymorphisms, genotypic testing method,
127number of cases and controls, genotype frequency of
128cases and controls, minor allele frequencies in control
129subjects, and result of Hardy–Weinberg equilibrium
130(HWE) test in control subjects. In this meta-analysis,
131ethnicity was categorized as: Caucasian, Asian, and
132Mixed.
133Inclusion and exclusion criteria
134To be included in the meta-analysis, studies had to meet
135all the criteria: (1) use a case–control or cohort design;
136(2) assess the association of the XRCC3 18067 C>T
137polymorphism with ovarian and cervical cancers; and
138(3) provide sufficient data for estimating odds ratios
139(ORs) with 95% confidence intervals (CIs). The exclusion
140criteria were: (1) studies that could not offer the number
141of cases and controls or other essential information;
142(2) case only or studies without control group; (3) family
143based or linkage studies; (4) case reports, reviews, and
144studies; and (5) overlapping data. In the case of multiple
145studies by the same researchers involving the same or
146overlapping data sets, the most recent study with the
147largest number of participants was included in the meta-
148analysis.
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149 Statistical analyses
150 The strength of association of the XRCC3 18067 C>T
151 polymorphism with ovarian and cervical cancers suscep-
152 tibility was assessed by OR with the corresponding 95%
153 CI. The Z-test was performed to determine the signifi-
154 cance of the pooled OR, with p< 0.05 defined as the
155 significance threshold. The pooled ORs were calculated
156 for the risk associated with the XRCC3 18067 C>T
157 polymorphism in the allele model (T vs. C), homozygote
158 model (TT vs. CC), heterozygote model (TC vs. CC),
159 dominant model (TT+TC vs. CC), and recessive model
160 (TT+TC vs. CC). The between-studies heterogeneity
161 was tested using the Q statistic. If p< 0.10, the hetero-
162 geneity was considered statistically significant. Venice
163 criteria for the I2 test included: I2< 25% represents no
164 heterogeneity, I2= 25%–50% represents moderate
165 heterogeneity, I2= 50%–75% represents large heteroge-
166 neity, and I2> 75% represents extreme heterogeneity.
167 The p value of <0.05 for the Q-test indicated a lack of
168 heterogeneity among studies, so that the pooled OR
169 estimate of each study was calculated by the fixed-effects
170 model (the Mantel–Haenszel method), otherwise the
171 random effects model (the DerSimonian–Laird method)
172 was utilized. Furthermore, to explore the source of
173 between-study heterogeneity, the subgroup analyses were
174 performed. The one-way sensitivity analyses were
175 performed to survey the stability of the results, namely,
176 a single study in the meta-analysis was omitted each time
177 to reflect the influence of the individual data set to the
178 pooled OR. Publication bias was assessed by visually
179 examining the asymmetry of a funnel plot in which the
180 log estimates were plotted against their standard errors.
181 Furthermore, we also employed an Egger’s regression test
182 in our analysis to calculate two-tailed p values for quanti-
183 fying publication bias. A HWE test of the VDR gene
184 polymorphisms in healthy subjects was examined using χ2
185 test. If p value > 0.05, the genotype distribution of the
186 control group conformed to HWE. All the statistical
187 analyses were performed by comprehensive meta-analysis
188 version 2.0 software (Biostat, USA). All the p values were
189 two sides and less than 0.05 were considered significant.
190 Results
191 Study selection and characteristics
192 A flow diagram schematizing the inclusion and exclusion
193 process of identified articles with the inclusion criteria is
194 presented in Fig. 1. After a comprehensive search, a total
195 of 126 literatures were identified. Of these studies, the
196 first screening excluded 47 were considered as duplicates
197 or not relevant, leaving 79 studies for further selection.
198 Finally, a total of 17 case–control studies (in 14 publica-
199 tions) were included in this meta-analysis [18–31].
200Of these, there were seven studies with 1,112 cases and
2011,233 controls on cervical cancer [18–24] and 10 studies
202with 5,637 cases and 9,267 controls on ovarian cancer
203[25, 27–31]. The main characteristics of studies included
204in the present meta-analysis are presented in Table I. Of
205all the eligible studies, four were conducted in Asian, two
206were in Caucasians, and one was in mixed for cervical
207cancer; eight were conducted in Caucasians and two were
208in mixed for ovarian cancer. Twelve studies were popula-
209tion-based and four were hospital-based studies. One
210study in the present meta-analysis did not state the source
211of controls. Four genotyping methods were used,
212including AS-PCR, PCR-RFLP, PyrosequencingTM, and
213TaqMan assay. The genotype distributions among the
214controls in two studies were not consistent with HWE on
215ovarian cancer (Table I).
216Quantitative synthesis
217Table II listed the main results of the meta-analysis of
218XRCC3 18067 C>T polymorphism with cervical and
219ovarian cancers risk. When all the eligible studies were
220pooled into meta-analysis, the results showed that
221XRCC3 18067 C>T polymorphism was not significantly
222associated with increased risk of cervical and ovarian
223cancers under all genetic models genetic models,
224i.e., allele (T vs. C: OR= 1.014, 95% CI= 0.930–
2251.106, p= 0.745), homozygote (TT vs. CC: OR=
2261.010, 95%=CI 0.855–1.194, p= 0.906), heterozygote
227(TC vs. CC: OR= 0.967, 95% CI = 0.876–1.067,
228p= 0.530), dominant (TT+TC vs. CC: OR= 0.993,
22995% CI= 0.889–1.108, p= 0.897), and recessive
230(TT vs. TC+CC: OR= 1.028, 95% CI= 0.894–
2311.183, p= 0.700).
232The studies were further stratified by cancer type and
233ethnicity. When stratified by cancer, there was a signifi-
234cant association between XRCC3 18067 C>T polymor-
235phism and increased risk of cervical cancer under the
236heterozygote model (TC vs. CC: OR= 1.00, 95%
237CI= 1.066–1.585, p= 0.009; Fig. 2A). Moreover Q7, the
238XRCC3 18067 C>T polymorphism was significantly
239associated with increased risk of ovarian cancer under
240two genetic models, i.e., heterozygote (TC vs. CC:
241OR= 0.904, 95% CI = 0.841–0.972, p= 0.006) and
242dominant (TT+TC vs. CC: OR= 0.914, 95%
243CI= 0.853–0.979, p= 0.010; Fig. 2B).
244Subgroup analysis by ethnicity showed that there was a
245significant association between XRCC3 18067 C>T
246polymorphism and cervical cancer in Asian under three
247genetic models, i.e., model (T vs. C: OR= 1.302, 95%
248CI= 1.076–1.576, p= 0.007), heterozygote (TC vs. CC:
249OR= 1.441, 95% CI = 1.113–1.867, p= 0.006) and
250dominant (TT+TC vs. CC: OR= 1.469, 95% CI=
2511.148–1.880, p= 0.002), but not in Caucasians. More-
252over, subgroup analysis showed that there was a
XRCC3 18067 C>T and cervical and ovarian cancers
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253 significant association between XRCC3 18067 C>T poly-
254 morphism and increased risk of ovarian cancer in Cauca-
255 sians under two genetic models, i.e., heterozygote (TC vs.
256 CC: OR= 0.898, 95% CI= 0.834–0.967, p= 0.004) and
257 dominant (TT+TC vs. CC: OR= 0.905, 95% CI=
258 0.844–0.970, p= 0.005). In the subgroup analyses by
259 ethnicity, no studies were performed for ovarian cancer
260 in Asians suggesting that our results might be not applica-
261 ble for these populations.
262Test of heterogeneity and sensitivity analyses
263For cervical cancer, statistical significant heterogeneity
264among studies under four genetic models was observed
265when all eligible studies were pooled into the meta-
266analysis. However, the heterogeneity test showed that
267there was no significant heterogeneity in terms of
268the XRCC3 18067 C>T polymorphism association
269with ovarian cancer. Therefore, to explore the potential
Fig. 1.Q6
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270 sources of heterogeneity across studies, we performed
271 subgroup analysis under all models. To explore the
272 sources of heterogeneity, we conducted subgroup analy-
273 ses by ethnicity, genotyping methods, and source of
274 controls. Subgroup analyses by ethnicity showed that the
275 heterogeneity was still significant in Caucasians popula-
276 tions, indicating that ethnicity was the major source that
277 contributed to heterogeneity for cervical cancer. In
278 addition, we have performed sensitivity analyses to assess
279 the influence of each individual study on the pooled ORs
280 by sequential omission of individual studies. The results
281 suggested that the sequential omission of individual
282 studies did not significantly affect the pooled ORs for
283 the XRCC3 18067 C>T polymorphism, the stability of
284 the current meta-analysis results. For ovarian cancer,
285 sensitivity analysis was further performed by excluded
286 one HWE-violating study. However, the XRCC3
287 18067 C>T polymorphism association with ovarian can-
288 cer risk was not influenced by omitting the study.
289Publication bias
290Both Begg’s funnel plot and Egger’s test were performed
291to assess the publication bias of literatures in all genetic
292models and by ethnicity. The shape of the funnel plot did
293not reveal any evidence of obvious asymmetry in overall
294and by cancer type (Fig. 3). Then, we used the Egger’s
295test to provide statistical evidence of funnel plot symme-
296try. The results still did not suggest any evidence of
297publication bias in overall, by cancer type and ethnicity
298(Table II).
299Discussion
300The XRCC3 gene is one of the major genes involved in
301the restoration phase of DNA damage [14]. More than
302300 validated single nucleotide polymorphisms in the
303XRCC3 gene were reported in the dbSNP database
Fig. 2.
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304 among them, 18067 C>T (rs861539) in XRCC3 codon
305 241 (Thr241Met) was the most extensively studied in
306 different malignancies [16, 17]. There is evidence that
307 XRCC3 18067 C>T polymorphism is a functional
308 variant with potential to affect the capacity of DNA repair
309 activity [15]. The association of this polymorphism with
310 cervical and ovarian cancer risk has been assessed in
311 several studies, which showed inconclusive results.
312 In the present meta-analysis, we examined the associ-
313 ation of XRCC3 18067 C>T polymorphism with cervical
314 and ovarian cancers risk. We found that the XRCC3
315 18067 C>T polymorphism was significantly associated
316 with ovarian cancer risk. We also observed a significant
317 relationship between the XRCC3 18067 C>T polymor-
318 phism and ovarian cancer in Caucasians. However, our
319 results were inconsistent with previous meta-analysis. Yan
320 et al. [16] in a meta-analysis of seven studies with 3,635
321 cases and 5,473 controls suggested that the XRCC3
322 18067 C>T polymorphism may not be associated with
323 ovarian cancer in all five genetic models in overall and
324 Caucasians population. In 2013, Qin et al. [17] in a meta-
325 analysis of five case–control studies with a total of 806
326 cervical cancer cases and 850 controls estimated the
327 association between XRCC3 18067 C>T polymorphism
328 and cervical cancer risk. The results showed a significant
329 association that XRCC3 18067 C>T polymorphism may
330 contribute to the susceptibility of cervical cancer only
331 under heterozygote model. The association was further
332 confirmedQ9 by our meta-analysis, which involved seven
333 studies with 1,112 cases and 1,233 controls only in the
334 heterozygote model. Moreover, the previous [16] and
335 the current meta-analyses findings confirmed that
336 XRCC3 18067 C>T polymorphism is associated with
337 the risk of cervical cancer among Asians, but not among
338 Caucasians, suggesting that this polymorphismmay mod-
339 ify the risk of cervical cancer in different ethnicities.
340 Compared to the previous meta-analyses, the included
341 studies to the current meta-analysis are most precise and
342 comprehensive attributing to the largest sample size and
343accumulative meta-analysis method. Hence, our results
344are more precise and comprehensive on the association of
345XRCC3 18067 C>T polymorphism with cervical and
346ovarian cancers.
347The heterogeneity plays an important role when
348performing meta-analysis and finding the source of het-
349erogeneity is very important for the final result of
350meta-analysis. There were several sources bringing in
351heterogeneity, such as study design, age, sex distribution,
352sample size, genotyping methods, and ethnicity. Obvi-
353ously, there was potential to moderate level heterogeneity
354in the current meta-analysis. Thus, we have performed
355meta-regression analysis to find source of heterogeneity.
356The heterogeneity between our studies was significantly
357reduced in the analysis of the cancer type and by ethnicity
358subgroups, indicating that the effect of XRCC3 18067
359C>T polymorphism may be modified by cancer etiology
360and ethnicity backgrounds.
361The main advantage of our meta-analysis that publi-
362cation bias was not observed, which indicates that the
363whole pooled results, may be unbiased. However, several
364limitations in this meta-analysis should be addressed.
365First, the included studies only provided data toward
366Asians and Caucasians. The data regarding other ethnici-
367ties such as Africans were not found. Therefore, we
368cannot generalize these findings to every ethnic group.
369Second, there were only seven studies with a total of
3701,112 cases and 1,233 controls that were finally included
371into the meta-analysis for cervical cancer. The number of
372included studies was relatively limited, which may
373increase the risk of bias in the meta-analysis, especially
374in the subgroup analysis by ethnicity. Thus, more studies
375with a larger sample size from different ethnicities should
376be performed in the future. Third, we have included
377only published studies in the meta-analysis, and non-
378significant or negative findings may be unpublished.
379Hence, any preexisting publication bias will be reflected
380in the findings; however, the statistical data may not show
381it. Fifth, the summary ORs were based on individual
Fig. 3.Q8
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382 unadjusted estimates, while a more precise analysis might
383 be performed if detailed individual data were available,
384 which could allow for an adjusted estimation by age,
385 obesity, hormone replacement therapy, reproductive
386 history and infertility, gynecologic surgery, and environ-
387 ment factors. Lack of information for data analysis may
388 cause serious confounding bias. Finally, gene–gene and
389 gene–environment interactions may have influenced our
390 findings, as ovarian and cervical cancers are mainly caused
391 by genetic and environmental factors. However, these
392 interactions were not tested in the current meta-analysis
393 because of the lack of sufficient data.
394 In summary, our meta-analysis demonstrated that the
395 XRCC3 18067 C>T polymorphism may be associated
396 with increased risk of cervical and ovarian cancers.
397 Moreover, the XRCC3 18067 C>T polymorphismmight
398 be a potential risk factor for cervical cancer among Asians
399 and for ovarian cancer among Caucasians. However, to
400 validate this association and our findings further, large
401 and well-designed epidemiological studies are warranted.
402 * * *
403 Funding sources: None.
404 Authors’ contribution: MK-Z and MM contributed to conception of
405 the study, writing and editing the paper, and validation of the final
406 version. HA, AH, and R-ST searched literature, selected study, and
407 drafted the article. HN analyzed the data. HN and AJ contributed to
408 interpretation of data, writing and editing of the paper, and validation of
409 the final version of the manuscript.
410 Conflict of interest: The authors declare no competing interest.
411 Acknowledgements: The authors would like to thank Prof. Seyed
412 Mehdi Kalantar for his intellectual guidance.
413 References
414 1. Kamali M, Hamadani S, Neamatzadeh H, Mazaheri M, Zare
415 Shehneh M, Modaress Gilani M, Haghighi F: Association of
416 XRCC2 rs3218536 polymorphism with susceptibility of breast and
417 ovarian cancer: A systematic review and meta-analysis. Asian Pac
418 J Cancer Prev 18,1743–1749 (2017)
419 2. Razi S, Ghoncheh M, Mohammadian-Hafshejani A, Aziznejhad H,
420 Mohammadian M, Salehiniya H: The incidence and mortality of
421 ovarian cancer and their relationship with the Human Development
422 Index in Asia. Ecancermedicalscience 10, 628 (2016)
423 3. Burd EM: Human papillomavirus and cervical cancer. Clin
424 Microbiol Rev 16, 1–17 (2003)
425 4. Moorman PG, Palmieri RT, Akushevich L, Berchuck A, Schildkraut
426 JM: Ovarian cancer risk factors in African–American and White
427 women. Am J Epidemiol 170, 598–606 (2009)
428 5. Murillo R, Herrero R, Sierra MS, Forman D: Cervical cancer in
429 Central and South America: Burden of disease and status of disease
430 control. Cancer Epidemiol 44, S121–S130 (2016)
431 6. Fey MC, Beal MW: Role of human papilloma virus testing in cervical
432 cancer prevention. J Midwifery Womens Health 49, 4–13 (2004)
433 7. Beehler GP, Sekhon M, Baker JA, Teter BE, McCann SE,
434 Rodabaugh KJ, Moysich KB: Risk of ovarian cancer associated with
435 BMI varies by menopausal status. J Nutr 136, 2881–2886 (2006)
4368. Chen D, Enroth S, Liu H, Sun Y, Wang H, Yu M, Deng L, Xu S,
437Gyllensten U: Pooled analysis of genome-wide association studies of
438cervical intraepithelial neoplasia 3 (CIN3) identifies a new
439susceptibility locus. Oncotarget 7, 42216–42224 (2016)
4409. Haruta S, Furukawa N, Yoshizawa Y, Tsunemi T, Nagai A,
441Kawaguchi R, Tanase Y, Yoshida S, Kobayashi H: Molecular
442genetics and epidemiology of epithelial ovarian cancer (Review).
443Oncol Rep 26, 1347–1356 (2011)
44410. Ferguson LR, Chen H, Collins AR, Connell M, Damia G, Dasgupta
445S, Malhotra M, Meeker AK, Amedei A, Amin A, Ashraf SS, Aquilano
446K, Azmi AS, Bhakta D, Bilsland A, Boosani CS, Chen S, Ciriolo MR,
447Fujii H, Guha G, Halicka D, Helferich WG, Keith WN, Mohammed
448SI, Niccolai E, Yang X,Honoki K, ParslowVR, Prakash S, Rezazadeh
449S, Shackelford RE, Sidransky D, Tran PT, Yang ES, Maxwell CA:
450Genomic instability in human cancer: Molecular insights and oppor-
451tunities for therapeutic attack and prevention through diet and
452nutrition. Semin Cancer Biol 35, S5–S24 (2015)
45311. He X-F, Liu L-R, Wei W, Liu Y, Su J, Wang SL, Shen XL, Yang XB:
454Association between the XPG Asp1104His and XPF Arg415Gln
455polymorphisms and risk of cancer: A meta-analysis. Veitia RA, ed.
456PLoS One 9, e88490 (2014)
45712. Zhu M-L, Wang M, Cao Z-G, He J, Shi TY, Xia KQ, Wei Q:
458Association between the ERCC5 Asp1104His polymorphism and
459cancer risk: A meta-analysis. PLoS One 7, e36293 (2012)
46013. Namazi A, Abedinzadeh M, Nourbaksh P, Neamatzadeh H:
461Association between the XRCC3 Thr241Met polymorphism and
462risk of colorectal cancer: A meta analysis of 5, 193 cases and 6, 645
463controls. Asian Pac J Cancer Prev 16, 2263–2268 (2015)
46414. Sobhan MR, Forat Yazdi M, Mazaheri M, Zare Shehneh M,
465Neamatzadeh H: Association between the DNA repair gene XRCC3
466rs861539 polymorphism and risk of osteosarcoma: A systematic review
467and meta-analysis. Asian Pac J Cancer Prev 18, 549–555 (2017)
46815. Mucha B, Przybylowska-Sygut K, Dziki AJ, Dziki L, Sygut A,
469Majsterek I: Association of Thr241Met polymorphism of XRCC3
470gene with risk of colorectal cancer in the Polish population. Pol J
471Pathol 64, 185–190 (2013)
47216. Yan Y, LiangH, Li R, Xie L, Li M, Li S, Qin X: XRCC3Thr241Met
473polymorphism and ovarian cancer risk: A meta-analysis. Tumour
474Biol 35(3), 2711–2715 (2014)
47517. Qin L-Y, Chen X, Li P, Yang Z, Mo W-N: Association between the
476XRCC3 Thr241Met polymorphism and cervical cancer risk: A
477meta-analysis. Asian Pac J Cancer Prev 14, 6703–6707 (2014)
47818. He X, Ye F, Zhang J, Cheng Q, Shen J, Chen H: Susceptibility of
479XRCC3, XPD, and XPG genetic variants to cervical carcinoma.
480Pathobiology 75, 356–363 (2008)
48119. Xiao H: The association between XRCC3 gene polymorphism and
482cervical cancer risk. Jilin Med 31, 2731–2732 (2009)
48320. Settheetham-Ishida W, Yuenyao P, Natphopsuk S, Settheetham D,
484Ishida T: Genetic risk of DNA repair gene polymorphisms (XRCC1
485and XRCC3) for high risk human papillomavirus negative cervical
486cancer in Northeast Thailand. Asian Pac J Cancer Prev 12, 963–966
487(2011)
48821. Pérez LO, Crivaro A, Barbisan G, Poleri L, Golijow CD: XRCC2
489R188H (rs3218536), XRCC3 T241M (rs861539) and R243H
490(rs77381814) single nucleotide polymorphisms in cervical cancer
491risk. Pathol Oncol Res 19, 553–558 (2013)
49222. Djansugurova LB, Perfilyeva A V, Zhunusova GS, Djantaeva KB,
493Iksan OA, Khussainova EM: The determination of genetic markers
494of age-related cancer pathologies in populations from Kazakhstan.
495Front Genet 4, 70 (2013)
49623. Colacino-Silva F, Ferreira De Oliveira Kleine JP, Salzgeber MB, de
497Aquino Castro R, Girão MJBC, da Silva IDCG, D’Amora P:
498Polymorphic DNA repair genes XRCC1 and XRCC3 and the risk
499for cervical cancer in brazilian patients [Polimorfismos Nos Genes
500de Reparo Do DNA XRCC1 E XRCC3 E O Risco Para O Câncer
501Cervical Uterino Em Pacientes Brasileiras]. Braz J Oncol 13 (2017)
XRCC3 18067 C>T and cervical and ovarian cancers
Interventional Medicine & Applied Science 9 ISSN 2061-1617 © 2019 The Author(s)
502 24. Al-Harbi NM, Bin Judia SS, Mishra KN, Shoukri MM, Alsbeih GA:
503 Genetic predisposition to cervical cancer and the association with
504 XRCC1 and TGFB1 polymorphisms. Int J Gynecol Cancer 27,
505 1949–1956 (2017)
506 25. Auranen A, Song H, Waterfall C, Dicioccio RA, Kuschel B, Kjaer
507 SK, Hogdall E, Hogdall C, Stratton J, Whittemore AS, Easton DF,
508 Ponder BA, Novik KL, Dunning AM, Gayther S, Pharoah PD:
509 Polymorphisms in DNA repair genes and epithelial ovarian cancer
510 risk. Int J Cancer 117, 611–618 (2005)
511 26. Webb PM, Hopper JL, Newman B, Chen X, Kelemen L, Giles GG,
512 Southey MC, Chenevix-Trench G, Spurdle AB: Double-strand
513 break repair gene polymorphisms and risk of breast or ovarian
514 cancer. Cancer Epidemiol Biomarkers Prev 14, 319–323 (2005)
515 27. Beesley J, Jordan SJ, Spurdle AB, Song H, Ramus SJ, Kjaer SK,
516 Hogdall E, DiCioccio RA, McGuire V, Whittemore AS, Gayther
517 SA, Pharoah PD, Webb PM, Chenevix-Trench G: Association
518 between single-nucleotide polymorphisms in hormone metabolism
519 and DNA repair genes and epithelial ovarian cancer: Results from
520 two Australian studies and an additional validation set. Cancer
521 Epidemiol Biomarkers Prev 16, 2557–2565 (2007)
52228. Gonzalez-Hormazabal P, Reyes JM, Blanco R, Bravo T, Carrera I,
523Peralta O, Gomez F, Waugh E, Margarit S, Ibañez G, Santos JL,
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